
- Volume 0 0
Lithium Carbonate ER
Roxane Laboratories Inc (Columbus,Ohio) recently announced the approval ofLithium Carbonate Extended ReleaseTablets USP, 450 mg. This product is ABratedto GlaxoSmithKline?s Eskalith CR(lithium carbonate) 450 mg. LithiumCarbonate Extended Release Tablets areindicated for the treatment of manicepisodes of manic?depressive illness.Maintenance therapy prevents or diminishesthe intensity of subsequentepisodes in those manic?depressivepatients with a history of mania. Thetablets may produce a normalization ofsymptomatology within 1 to 3 weeks. Formore information, visit www.roxane.com.
Articles in this issue
over 21 years ago
Interface Speeds Up Prescription Fillingover 21 years ago
New Technologies Top Surveyover 21 years ago
Partnership Addresses Packaging Solutionsover 21 years ago
PDX Software Gets High Marksover 21 years ago
Polar Powder Cold Pak with Magnetic Therapyover 21 years ago
Seal•ONover 21 years ago
SaltAire Sinus Reliefover 21 years ago
Zim's Crack Creme Hand Sanitizerover 21 years ago
CoroWise Plant Sterolsover 21 years ago
CulturelleNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.